uniQure N.V. (QURE) Dividend History

uniQure N.V. is a biotechnology company focused on developing gene therapy treatments for genetic and other life-threatening diseases. Founded in the Netherlands, it specializes in delivering gene therapies using adeno-associated virus (AAV) vectors to address rare, serious conditions such as hemophilia and neurological disorders.

Paasheuvelweg 25a, Amsterdam, P7, 1105 BP
Phone: 1-339-970-7000
Website: https://www.uniqure.com

Dividend History

uniQure N.V. currently does not pay dividends

Company News

CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B

CSL Behring's gene therapy HEMGENIX has shown sustained efficacy and safety in treating adults with hemophilia B, with 94% of patients remaining free of continuous prophylaxis treatment four years after a single infusion.

Benzinga
uniQure Announces Proposed Public Offering

uniQure, a gene therapy company, has announced a proposed public offering of its ordinary shares and pre-funded warrants. The offering is subject to market conditions and underwriter approval.

GlobeNewswire Inc.
Gene Therapy Market Size to Reach USD 54.39 Billion By 2032 with CAGR of 23.12%, Boosted by Rising Genetic Disorders and Advances in CRISPR Technology

The global gene therapy market is expected to grow significantly, driven by technological advancements, increased R&D investment, and the rising prevalence of genetic disorders. Key players in the market are focusing on developing transformative gene therapy platforms and expanding their capabilities through strategic collaborations and acquisitions.

GlobeNewswire Inc.

Featured Companies: AMGN BIIB BLUE BMRN BMY EDIT GILD MRK PFE RGNX SGMO SRPT VYGR
Kura Sushi Posts Weak Q3 Results, Joins LegalZoom.com And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga

Kura Sushi USA reported weak Q3 results, missing analyst estimates. Several other companies, including LegalZoom.com, Stardust Power, 10x Genomics, IDEAYA Biosciences, and uniQure, also saw their shares decline in pre-market trading.

Benzinga

Featured Companies: IDYA KRUS LZ TXG
Crude Oil Down 1%; Soligenix Shares Surge - Helen Of Troy (NASDAQ:HELE) - Benzinga

Crude oil prices declined by 1%, while shares of Soligenix surged 282% after the company announced positive interim results for its HyBryte treatment. Helen of Troy reported soft Q1 earnings and lowered its FY25 guidance, leading to a 30% drop in its stock price.

Benzinga

Featured Companies: CLNN HELE SNGX

Dividend data last updated 06/07/2025 07:35:04 UTC